What Rite Aid’s First Quarter Results Reveal About the Health of Its Business

Rite Aid reported quarterly earnings before the market opened today. You might be surprised by the results.

Jun 19, 2014 at 2:24PM

Rite Aid (NYSE:RAD) reported its fiscal 2015 first-quarter earnings before the market opened today. Unfortunately for Rite Aid shareholders, Mr. Market was unimpressed. The stock fell more than 3% this morning to trade around $7.20 a share. It is worth mentioning, however, that Rite Aid actually beat Wall Street's revenue projections for the quarter, and the company's earnings were in line with analysts' estimates. Let's dig deeper to uncover what Rite Aid's first-quarter results tell us about the overall health of its business.

A brief recap
Here are some highlights from the drugstore chain's first quarter. Rite Aid posted a profit of $0.04 per diluted share. This met the Street's profit estimate for the period. However, the larger issue was that it marked a 55% decline in profit from the same period a year ago. Revenue offered a somewhat brighter picture, climbing 3% to $6.5 billion, up from $6.3 billion in the first-quarter of fiscal 2014. This topped Wall Street's expectations for revenue of $6.43 billion in the quarter, albeit marginally.

Rite Aid's quarterly comparable sales also offered a bit of breathing room. Same-store sales increased 3.1% in the quarter, while pharmacy same-store sales climbed 4.6%. Comparable sales, or same-store sales, is a key metric for retail stocks, because it measures the performance of stores open at least a year. This can help investors get a more accurate read on the operational health of the business. In this case, Rite Aid's positive comps tell us that its pharmacy business is gaining traction.

Beyond the numbers
The fact that customers filled more prescriptions at Rite Aid's pharmacies during the quarter is something that should stand out for long-term investors in this name. Specifically, Rite Aid said the number of prescriptions filled in stores open at least a year climbed 2.3% from a year ago. This is particularly important, because prescription sales made up more than 68% of Rite Aid's total drugstore sales in the quarter.

Prescription sales growth just north of 2% may not be cause for celebration. However, it suggests that Rite Aid's new Health Alliance program is helping drive new patients into Rite Aid pharmacies. Think of the Health Alliance initiative as a referral program. Physicians recommend the program to patients with chronic conditions such as high cholesterol or COPD, and Rite Aid pharmacists then work with the patient's doctor to create a "health care action plan" for managing their condition. This, in turn, drives more customers to Rite Aid's pharmacies. Not to mention these are higher value customers, as they often require regular prescription refills to treat their chronic conditions.

Rite Aid's Health Alliance is currently in four markets. Investors should see prescription sales grow at a faster clip as the company rolls the program into more markets in the quarters ahead.

Foolish takeaway
Rite Aid is still in the early stages of a turnaround, and as Foolish investors know, these things take time. Nevertheless, I believe the company is headed in the right direction. With more patients turning to retail pharmacies today for everyday health and wellness purposes, there is a major catalyst for this stock going forward.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Tamara Rutter has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information